REGN · Regeneron Pharmaceuticals

The thesis

Regeneron's shares are modestly more likely than not to beat the S&P 500 over the next three months. The reason is that its earnings have stepped up now that it keeps its full share of Dupixent profits, and EYLEA HD and Libtayo add growth on top. Three events settle it: the FDA's November 2026 decision on cemdisiran, the 4 December 2026 patent hearing on EYLEA HD, and the Q4 2026 report, which shows whether the higher profit level holds.

Regeneron reported on 30 October 2026. Revenue rose 36% to $5.116 billion. Non-GAAP earnings per share (EPS) were $20.07, against a $16.19 consensus estimate (Benzinga). Investing.com reported that Q3 was the first full quarter after Regeneron finished repaying the Dupixent development balance. Sanofi collaboration revenue reached a record $2.724 billion. The view is that the higher profit share carries into later quarters. Q4 collaboration revenue below $2.724 billion, excluding the one-time $1.0 billion Sanofi upfront, would show that view is wrong.

The rating is Medium. The earnings step-up is filed and large, and the pipeline added two positive mid-stage readouts in one week (8 November 2026 and 12 November 2026). The valuation is not stretched: Wells Fargo projects about $83 of 2027 EPS, which Investing.com put at about 11 times earnings at a $916 share price (12 November 2026). Against that, directors and executives sold after option exercises at $942 to $971 in early November. An Alvotech patent challenge also puts part of EYLEA HD's long-term protection in question.

The price already reflects much of the Q3 beat and the liver data. The shares closed at $951.19 on 12 November 2026, up 18.5% over three months on adjusted daily closes, and most brokers had raised their targets by 5 November 2026.

Bullish and bearish views on Regeneron Pharmaceuticals, Inc.

The bull case on Regeneron Pharmaceuticals, Inc. (REGN), in brief: the full Dupixent profit share is flowing. The bear case: directors sold after the report.

Bull case

• The full Dupixent profit share is flowing. Sanofi records Dupixent sales, which reached $6.541 billion worldwide in Q3 2026, up 35% (Regeneron 8-K, 30 October 2026). Q3 was the first full quarter after the development balance was repaid (Investing.com, 2 November 2026).
• EYLEA HD demand is still rising. U.S. EYLEA HD sales were $699 million in Q3 2026, up 62% from a year earlier and 17% from the prior quarter (Investing.com, 2 November 2026). Management guided to about 10% sequential demand growth in Q4.
• Libtayo has become a growth product. Worldwide Libtayo sales rose 51% to $550 million in Q3 2026 (8-K, 30 October 2026). Updated Phase 3 C-POST results at the European Society for Medical Oncology (ESMO) meeting on 25 October 2026 showed a 37% lower risk of death than placebo in high-risk cutaneous squamous cell carcinoma, a type of skin cancer.
• Cemdisiran is the nearest new launch. The FDA is reviewing it for generalized myasthenia gravis under priority review, with a November 2026 target date (NeurologyLive, 22 June 2026). The Phase 3 NIMBLE trial showed a 2.3-point placebo-adjusted improvement on the 24-point daily-activities scale at 24 weeks. It would be the first small interfering RNA (siRNA) drug for the disease, dosed under the skin four times a year.
• A second mid-stage readout landed on 12 November 2026. In the Phase 2 PINNACLE trial in postural orthostatic tachycardia syndrome (POTS), a condition with no FDA-approved treatment, one 450 mg dose of baloncibart cut the standing heart-rate rise by 11.4 beats per minute versus placebo at day 8 and by 7.4 at day 29 (company release, 12 November 2026). The trial enrolled 82 patients, and Regeneron plans a potentially pivotal Phase 3 trial in the first half of 2027.
• The liver program produced strong early data. One dose of CIDEBsiRNA cut liver fat by 58% to 80% at week 36, against 2.9% on placebo, and 62% of treated patients reached normal liver fat (company release, 8 November 2026). The results appeared in The New England Journal of Medicine (Benzinga, 10 November 2026).
• Brokers keep targets above the price. Jefferies reiterated its Buy rating and $1,065 target ahead of the patent hearing (Investing.com, 12 November 2026). BofA Securities' Tazeen Ahmad kept a Buy rating and $1,030 target on 11 November 2026, Guggenheim is at $1,100, and DZ Bank raised its target to $1,067 from $900 on 5 November 2026.
• The balance sheet funds buybacks. Cash and marketable securities were $18.9 billion on 30 September 2026. Regeneron repurchased $2.3 billion of stock in the first nine months of 2026 and had $2.2 billion of authorization left (8-K, 30 October 2026).

Bear case

• Directors sold after the report. SEC Form 4 filings show director George Sing sold 21,129 shares at an average $964.38 and director Christine Poon sold 7,830 shares at an average $969.09 on 2 November 2026. Director Huda Zoghbi sold 7,439 shares at an average $970.46 on 3 November 2026, each after exercising options.
• Executives sold too. General Counsel Joseph LaRosa sold 4,466 shares at an average $965.49 on 2 November 2026, and Controller Jason Pitofsky sold 4,062 shares at an average $942.19 on 4 November 2026 (SEC Form 4). Of the sales filed since 30 October 2026, only director Kathryn Guarini's 400 shares were marked as under a Rule 10b5-1 pre-arranged plan.
• An EYLEA HD patent faces a challenge. Alvotech filed a post-grant review against the EYLEA HD '036 patent, which could protect the 8 mg formulation until 2039. The Patent Trial and Appeal Board (PTAB) hears it on 4 December 2026 and is expected to rule by 3 March 2027 (Investing.com, 12 November 2026). Jefferies cites an expert estimate of a 60% to 70% chance that Regeneron prevails.
• Some brokers sit well below the price. Morgan Stanley (Equal-Weight) raised its target only to $855, and Bernstein (Market Perform) to $812, on 2 November 2026 (Benzinga). Wells Fargo's target is $925 (Investing.com, 12 November 2026).
• Legacy EYLEA keeps shrinking. EYLEA HD growth has to offset the decline of the original 2 mg EYLEA, which faces biosimilar and pricing pressure. A flat EYLEA HD quarter would expose that gap.
• The prefilled syringe has slipped before. Management targets FDA approval of the EYLEA HD prefilled syringe by year-end 2026, after earlier delays tied to third-party manufacturing.
• The new pipeline data are small and early. The CIDEBsiRNA trial dosed 30 patients once, with safety as the primary goal, and one treated patient had a serious high-blood-sugar event the company attributed to adult-onset Type 1 diabetes (company release, 8 November 2026). The PINNACLE results carry nominal p-values, and the 150 mg baloncibart dose lost its effect by day 29 (company release, 12 November 2026).

Price setup

The shares closed at $951.19 on 12 November 2026, down from $959.41 on 11 November 2026. That is 4.1% below the 52-week intraday high of $991.73, set on 4 November 2026. Since that high, closes have ranged from $902.90 (5 November 2026) to $959.41 (11 November 2026).

On adjusted daily closes, the shares are up 18.5% over three months. They sit well above the 50-day moving average of $813.93 and the 200-day moving average of $744.80, both as of 12 November 2026. The 52-week closing low was $600.66 on 1 June 2026.

The levels that matter are the 4 November 2026 high and the early-November insider sale prices of $942 to $971, which mark where directors and executives sold. Below the price, the 5 November 2026 close of $902.90 is the low end of the post-report range. Broker targets run from Bernstein's $812 to Guggenheim's $1,100.

Catalysts ahead

• 17 November 2026: Regeneron presents at the Jefferies Global Healthcare Conference in London, 9:00 a.m. ET. A venue for updates on cemdisiran timing, the EYLEA HD prefilled syringe, the Alvotech patent challenge and the baloncibart Phase 3 plan.
• ~30 November 2026 (est.): FDA decision on cemdisiran for generalized myasthenia gravis (priority review, November 2026 target date). Approval adds the next new launch behind Dupixent and EYLEA HD; a rejection removes the nearest pipeline catalyst.
• 1 December 2026: Regeneron presents at the Evercore Healthcare Conference, then Citi's Global Healthcare Conference on 2 December 2026. Management comments would follow the expected cemdisiran decision and come just before the patent hearing.
• 4 December 2026: Patent Trial and Appeal Board hearing on Alvotech's challenge to the EYLEA HD '036 patent. The patent could protect the 8 mg EYLEA HD formulation until 2039; the hearing gives the first read on how the board views the challenge.
• ~31 December 2026 (est.): FDA decision on the EYLEA HD prefilled syringe, which management targets by year-end. A prefilled syringe makes EYLEA HD easier for doctors to use and supports the Q4 demand guidance.
• ~29 January 2027 (est.): Q4 2026 results. Shows whether collaboration revenue, excluding the $1.0B Sanofi upfront, holds at or above Q3's $2.724B, and whether U.S. EYLEA HD sales grew from $699M.
• ~3 March 2027 (est.): Expected PTAB final decision on the EYLEA HD '036 patent. A ruling for Regeneron keeps long-dated EYLEA HD protection in place; a loss opens an earlier path for 8 mg competitors.

What would change the view

A daily close below $850, which would put the shares under Morgan Stanley's $855 target and under every close from 4 November to 12 November 2026; or an FDA complete response letter for cemdisiran in November 2026.

The risks this note tracks, each with what would confirm it:

• The higher Dupixent profit share does not carry forward, and collaboration revenue slips from the Q3 2026 level. Confirmed by: Q4 2026 Sanofi collaboration revenue below $2.724B once the $1.0B upfront is excluded.
• EYLEA HD growth slows under pricing pressure and fails to offset the legacy EYLEA decline. Confirmed by: U.S. EYLEA HD sales flat or down from $699M in the Q4 2026 report while 2 mg EYLEA keeps falling.
• A cemdisiran regulatory setback delays the next launch. Confirmed by: an FDA complete response letter at the November 2026 target date.
• Alvotech's challenge weakens long-term EYLEA HD patent protection. Confirmed by: a PTAB final decision, expected by 3 March 2027, finding the '036 patent claims unpatentable.
• The EYLEA HD prefilled syringe slips again because of third-party manufacturing issues. Confirmed by: no FDA approval by 31 December 2026, or a new rejection tied to a filling site.
• Early liver and POTS data fail to hold in larger trials, removing pipeline options the market began pricing in November 2026. Confirmed by: a safety signal or weaker liver-fat response in the Phase 2 CIDEBsiRNA trials, or a baloncibart Phase 3 design that drops the 450 mg dose.
• Insider selling points to insiders seeing limited upside after the post-report run. Confirmed by: further Form 4 open-market sales by directors or executives outside Rule 10b5-1 plans before the Q4 2026 report.

What it trades with

Regeneron trades with large-cap biopharma and health-care indexes such as the Health Care Select Sector fund (XLV) and the iShares Biotechnology fund (IBB), but its November 2026 moves came from company events: the 30 October 2026 report, the 8 November 2026 liver data and the 12 November 2026 POTS data. Sanofi's reported Dupixent sales feed Regeneron's collaboration revenue directly, so a Sanofi quarterly report is a read-through for Regeneron. EYLEA HD competes in retinal disease with Roche's Vabysmo and with 2 mg aflibercept biosimilars, so their pricing affects Regeneron's ophthalmology line. BofA Securities added the stock to its "Value 10" list on 4 November 2026, which links it to value-style screens as well as to biotech sentiment.